Opexa Therapeutics, Inc. (OPXA)
-NasdaqCM 1.69 
0.07(4.32%) May 24, 3:59PM EDT
| Prev Close: | 1.62 |
|---|
| Open: | 1.62 |
|---|
| Bid: | 1.57 x 300 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 2.05 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.57 - 1.75 |
|---|
| 52wk Range: | 1.07 - 5.19 |
|---|
| Volume: | 156,852 |
|---|
| Avg Vol (3m): | 377,677 |
|---|
| Market Cap: | 13.64M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.75 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Opexa Therapeutics, Inc. [OPXA] to Ring The NASDAQ Stock Market Closing BellGlobeNewswire(Fri, May 24)
- OPEXA THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Tue, May 21)
- Q1 2013 OPEXA THERAPEUTICS INC Earnings Release - Before Market OpenCCBN(Tue, May 14)
- Opexa Therapeutics Reports First Quarter 2013 Financial Results and Provides Corporate UpdateBusiness Wire(Tue, May 14)
- OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 13)
- OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,EDGAR Online(Mon, May 13)
- Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2013 Financial ResultsBusiness Wire(Fri, May 10)
- The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Host 2nd International Vatican Adult Stem Cell ConferenceGlobeNewswire(Thu, Apr 11)
- Opexa Therapeutics to Present at the Regenerative Medicine - A Fundamental Shift in Science & Culture ConferenceBusiness Wire(Thu, Apr 4)
- Opexa Therapeutics Announces Changes to Senior Management TeamBusiness Wire(Mon, Apr 1)
- OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial StateEDGAR Online(Mon, Apr 1)
- OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Fri, Mar 29)
- Opexa Therapeutics Reports Year End 2012 Financial Results and Provides Corporate UpdateBusiness Wire(Thu, Mar 28)
- Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Hereat Seeking Alpha(Tue, Mar 26)
- Opexa: A Significant Growth Opportunity For Short-Term Traders And Long-Term Investorsat Seeking Alpha(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 59.40 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-11)
: | N/A |
|---|
| Quarterly EPS Est
(Sep-11)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology.
View More